• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Fresenius set to buy generics maker Akorn

April 10, 2017 By Sarah Faulkner

Report: Fresenius set to buy generics maker AkornGerman healthcare group Fresenius SE (NYSE:FMS) reportedly said last week that it is in talks with generic drugmaker Akorn Inc. (NSDQ:AKRX) for a potential takeover. Akorn shares jumped 10% to $32.60 on news of the potential bid.

Fresenius said in a statement that there is no guarantee that any deal will happen as a result of its talks with Akorn. The Illinois-based generics maker is valued at about $3.7 billion.

Akorn confirmed that it is in talks with Fresenius, adding that it won’t comment on the discussions until an agreement is reached by both parties.

Since Fresenius CEO Stephan Sturm took the helm in July, he has repeatedly demonstrated that he intends for acquisitions to be a defining characteristic of his time in the corner office.

In September, Fresenius made its biggest deal ever and acquired Spain’s private hospital chain Quironsalud for 5.8 billion euros ($6.14 billion).

Akorn brought in $1.1 billion in sales of generic pharmaceuticals last year, including nasal sprays, inhalants and eye-care therapies. The company has manufacturing facilities in the U.S., Switzerland and India and employs approximately 2,200 people.

Analysts reported that a Fresenius-Akorn merger would likely pass anti-trust scrutiny, as the companies don’t have too much overlap.

AKRX shares were trading at $32.81 apiece in mid-morning activity today, up 10.3%.

Material from Reuters was used in this report.

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Akorn, Fresenius

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS